The latest from NuvOx

Tucson, AZ – March 10, 2026 – Today NuvOx Therapeutics, Inc. (“NuvOx” or the “Company”) announced that the first patient has been treated under a U.S. Food and Drug Administration (FDA)-authorized single-patient Expanded Access protocol for newly diagnosed glioblastoma at the Center for Neurosciences. The treatment was administered by Dr. Michael Badruddoja and Dr. Matthew McFarlane, marking a significant milestone in NuvOx’s mission to address unmet needs in patients with a

Tucson, AZ  –March 4, 2026, NuvOx Therapeutics, Inc. (“NuvOx”) today announced that the U.S. Food and Drug Administration (FDA) has authorized NuvOx to proceed with a new Phase II clinical trial evaluating NuvOx’s product candidate NanO 2  (the active pharmaceutical ingredient of which is dodecafluoropentane) for the treatment of recurrent high-grade gliomas. The study, titled REBORN (Radiation Enhancement with Bevacizumab, Lomustine, Oxygen Replenishment, and NanO 2  [DDFPe]

Tucson, AZ  –December 15, 2025, NuvOx Therapeutics, Inc. (“NuvOx”) announced that the first patient has been  enrolled in the Phase IIb NOVEL trial (NanO 2  in Large Vessel Occlusion Stroke (NOVEL): a multicenter single-blind, randomized, placebo-controlled biomarker end point clinical trial of perfluorocarbon in acute ischemic stroke due to large vessel occlusion (LVO).  The NOVEL trial is funded by the Efficacy and Mechanism Evaluation (EME) Program, a partnership between t

Tucson, AZ  – November 24, 2025  – Today NuvOx Therapeutics, Inc. (“NuvOx”) along with Dr. Pavani Chalasani of George Washington University announced the acceptance of abstracts in Triple Negative Breast Cancer (TNBC) at 2 prestigious conventions, titled “Novel Oxygen Therapeutic Shows Promise in Boosting Immunotherapy Response in Triple Negative Breast Cancer”. Researchers at George Washington (GW) University Cancer Center, in collaboration with NuvOx, have demonstrated that

Tucson, Arizona — November 12, 2025 — NuvOx Therapeutics, Inc. (“NuvOx”), a clinical-stage biotechnology company developing oxygen therapeutics to enhance the efficacy of cancer treatment, today announced the progress from the ongoing RESTORE Phase IIb clinical trial of NanO₂™ in patients with newly diagnosed glioblastoma (GBM) will be presented at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting in Honolulu, HI. The presentation will be in a poster session by the Cen